Type 1 Diabetes

Hypoglycemia Following Antifungal Tx in Patient With Type 1 Diabetes

By November 07, 2018

"This is the first report of decreased insulin requirements in a patient with T1DM correlating with micafungin administration," noted the authors.

Ready-to-Use Glucagon Rescue Pen Under FDA Review for Severe Hypoglycemia Tx

By October 23, 2018

The NDA included findings from multiple Phase 3 trials evaluating the safety, efficacy, and utility of the Xeris glucagon rescue pen auto-injector to treat severe hypoglycemia vs currently available glucagon emergency kits in children, adolescents, and adults with type 1 diabetes.

Positive Results for Empagliflozin in Type 1 Diabetes Trials

By October 05, 2018

The EASE Phase 3 program included 2 double-blind, placebo-controlled trials investigating the efficacy and safety of empagliflozin as an adjunct to insulin therapy in adults with type 1 diabetes.

Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes

By July 10, 2018

For this study, researchers conducted a randomized, double-blind, placebo-controlled Phase 2 trial (N=24) to assess the efficacy and safety of adding oral verapamil for 12 months to a standard insulin regimen in adults with recent-onset type 1 diabetes (age range: 18 to 45 years).

BCG Vaccine Tied to Reduced Hyperglycemia in Type 1 Diabetes

June 22, 2018

Systemic shift in glucose metabolism from oxidative phosphorylation to aerobic glycolysis

Oral T1D Treatment Zynquista to Be Reviewed by FDA

By May 22, 2018

The NDA was supported by data from the Phase 3 inTandem clinical trial program which assessed the safety and efficacy of Zynquista in ~3000 adults with inadequately controlled type 1 diabetes.

Artificial Pancreas Treatment Efficacious for Type 1 Diabetes

April 20, 2018

Increased time in the near normoglycemic range and reduced time in hypo- and hyperglycemia

Sotagliflozin NDA Submitted to FDA for Type 1 Diabetes

By March 26, 2018

Sotagliflozin is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor.

Ozempic, Fiasp Now Available for the Treatment of Diabetes

By February 05, 2018

Both medications received approval from the FDA in 2017.

New Consensus Report Defines Clinically Meaningful T1D Outcomes

By November 22, 2017

To address this issue, the Type 1 Diabetes Outcomes Program was launched to develop consensus definitions for a set of priority outcomes for T1D.

Tool May Help Reduce Driving Mishaps Among T1D Patients

April 24, 2017

Researchers say new checklist can help determine when hypoglycemia should keep patients off the road

Self-Reported Ketone Testing Infrequent in T1D Patients

January 27, 2017

Thirty and 20 percent of participants, respectively, reported never and rarely checking ketones